Bayer & Meda v. Padagis: Azelastine Nasal Spray Dismissed Without Prejudice
Bayer AG and Meda Pharmaceuticals filed suit in the Delaware District Court against Padagis over three patents covering azelastine hydrochloride nasal spray (0.2055 mg/spray). The case was resolved by stipulated dismissal without prejudice in just 118 days, with each party bearing its own costs and attorneys’ fees.
Rapid stipulated exit in Delaware ANDA nasal spray dispute
On October 13, 2023, Bayer AG and Meda Pharmaceuticals Inc. filed a patent infringement action in the U.S. District Court for the District of Delaware (Case No. 1:23-cv-01148) against Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC. The suit asserted three patents — US8518919B2, US9919050B2, and US8071073B2 — covering azelastine hydrochloride nasal spray at a concentration of 0.2055 mg per spray, a higher-strength formulation of the antihistamine nasal spray.
The action ended on February 8, 2024, when all parties filed a stipulation of dismissal without prejudice pursuant to Federal Rules of Civil Procedure 41(a)(1) and 41(c). The dismissal was mutual: all claims and counterclaims asserted by either side were terminated, and each party agreed to bear its own legal costs. Because the dismissal was entered without prejudice, Bayer and Meda are not barred from reinstating claims on these patents in a future proceeding, and no merits determination was reached.
The 118-day resolution is notably short even for cases that settle, suggesting the parties may have reached a commercial accommodation or that the dispute dissolved for reasons not apparent from the public docket — such as a licensing arrangement, a change in Padagis’s ANDA filing strategy, or a negotiated consent agreement. The absence of any cost award and the symmetric ‘own costs’ clause is consistent with a negotiated exit rather than a one-sided capitulation. The precise commercial terms, if any, remain undisclosed.
Filing to voluntary dismissal in 118 days
118 days — resolved well before typical ANDA litigation timelines of 2–4 years
Dismissed without prejudice: what the stipulated exit means for both sides
Rule 41 stipulated dismissal: no merits ruling reached
Under FRCP 41(a)(1) and 41(c), parties may jointly stipulate to dismiss all claims and counterclaims without court adjudication. The ‘without prejudice’ designation means no res judicata bar attaches — Bayer and Meda are legally free to assert the same three patents against Padagis again if circumstances warrant. No finding of infringement, validity, or enforceability was made.
No merits adjudicationWithout prejudice preserves plaintiffs’ future enforcement options
A dismissal without prejudice is meaningfully different from one with prejudice. With prejudice would permanently bar re-filing on the same claims; without prejudice does not. Here, Bayer and Meda retain full ability to refile against Padagis on US8518919B2, US9919050B2, and US8071073B2 if Padagis pursues or relaunches a competing product. The public record does not disclose whether any licensing terms were agreed.
Refiling rights preservedPadagis avoids adverse ruling but faces unresolved patent exposure
Padagis exits this action without a validity or non-infringement finding in its favour. That means the three asserted patents remain presumptively valid and enforceable. Any future attempt by Padagis to commercialise an azelastine hydrochloride 0.2055 mg/spray product would likely require either a new challenge to these patents or a licence. The without-prejudice status keeps patent risk alive for Padagis’s product roadmap.
Patent risk unresolvedSector signal: early exits in ANDA suits often reflect licensing activity
In Hatch-Waxman litigation, rapid stipulated dismissals without prejudice are frequently associated with confidential licensing or consent agreements, launch-at-risk decisions being withdrawn, or ANDA amendments. The symmetric cost allocation here is consistent with a negotiated resolution. Competitors monitoring the azelastine nasal spray space should note that Bayer’s patent portfolio remains intact and unchallenged on the merits.
Licensing signal likelyFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bayer AG | Company | Pharmaceutical innovator Bayer AG — holder of US8518919B2, US9919050B2, US8071073B2Search in Eureka ↗ |
| Co-Plaintiff | Meda Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Defendant | Padagis Israel Pharmaceuticals, Ltd. | Company | Padagis Israel Pharmaceuticals Ltd. and affiliated U.S. entities — generic pharmaceutical filerSearch in Eureka ↗ |
| Co-Defendant | Padagis, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Padagis US, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Derek James Fahnestock | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff counsel | Rodger Dallery Smith , II | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Bayer AGSearch in Eureka ↗ |
| Defendant counsel | Stephen J. Kraftschik. | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant law firm | Polsinelli PC | Law Firm | Representing Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge William C. Bryson | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Official order — verbatim text
The stipulation invokes FRCP 41(a)(1) and 41(c) to achieve a clean bilateral exit: every claim and every counterclaim is extinguished simultaneously, with no admission of liability by either side. The ‘without prejudice’ qualifier is legally significant — it means this order carries no preclusive effect, leaving Bayer and Meda free to reassert the same patents. The symmetric cost clause, uncommon in contested ANDA litigation, is consistent with a privately negotiated accommodation underpinning the dismissal.
US8518919B2, US9919050B2 & US8071073B2 — azelastine hydrochloride nasal spray
The three asserted patents — US8518919B2, US9919050B2, and US8071073B2 — collectively cover the azelastine hydrochloride nasal spray product at the 0.2055 mg/spray strength. Filed across application numbers US13/294069, US13/974881, and US11/284109, these patents protect formulation compositions, excipient systems, and delivery characteristics of the higher-concentration intranasal antihistamine. Azelastine is a second-generation H1 receptor antagonist used for allergic rhinitis, and the 0.2055 mg/spray formulation represents a clinically differentiated product relative to the original 0.137 mg/spray strength.
Strategically, this three-patent cluster creates overlapping protection that is characteristic of a robust Orange Book listing strategy in ANDA litigation. By holding patents with different priority dates and claim orientations across the same product, Bayer and Meda can present a layered infringement theory that is more difficult for a generic challenger to design around. The absence of any invalidity or non-infringement ruling in this case means all three patents retain their presumption of validity — a meaningful deterrent to competing intranasal antihistamine development at this concentration.
Should your team run an FTO against US8518919B2, US9919050B2 & US8071073B2?
Any company developing a generic, biosimilar, or 505(b)(2) azelastine hydrochloride nasal spray at or near the 0.2055 mg/spray dose should treat these three patents as live enforcement risk. This case confirms Bayer and Meda are willing to litigate in Delaware on this portfolio, and the without-prejudice dismissal means the threat has not been neutralised. Formulators, CMOs, and ANDA sponsors working in the intranasal antihistamine space should evaluate independent claim scope across all three patents before filing or advancing an FDA submission.
PatSnap Eureka’s FTO Search Agent enables simultaneous claim-by-claim analysis across all three patent numbers, flagging freedom-to-operate gaps against your proposed formulation parameters. Eureka can also surface related divisionals, continuations, and Orange Book-listed counterparts that may extend the effective exclusivity window. Upload your formulation specifications to receive an AI-assisted risk heat map before committing to regulatory expenditure.
Run a freedom-to-operate analysis on US8518919B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA nasal spray patent cases in Delaware District Court
Explore comparable Hatch-Waxman infringement actions involving intranasal antihistamine or nasal spray formulation patents litigated in the Delaware District Court.
What this case signals for the intranasal antihistamine IP landscape
A fast exit in Delaware without prejudice keeps Bayer’s azelastine spray patents fully armed — and raises questions about Padagis’s next move.
Three azelastine patents survive unchallenged on the merits
US8518919B2, US9919050B2, and US8071073B2 have not been invalidated or found unenforceable in this action. Competitors developing generic or 505(b)(2) azelastine nasal spray products at the 0.2055 mg/spray strength should conduct a current FTO review against all three patents before progressing to clinical or regulatory stages.
Without-prejudice exit is a strategic holding pattern, not a resolution
The 118-day timeline and mutual cost-bearing clause suggest a negotiated accommodation rather than abandonment. Bayer retains full enforcement rights. If Padagis resumes its ANDA pathway, a re-filed suit — potentially on the same patents — is a realistic scenario. Portfolio monitors in the intranasal drug delivery space should track Padagis’s ANDA status with the FDA.
Bayer v Padagis — key questions answered
Bayer AG and Meda Pharmaceuticals filed a patent infringement suit against Padagis in Delaware on October 13, 2023 over three azelastine hydrochloride nasal spray patents. The case was dismissed without prejudice by stipulation on February 8, 2024 after 118 days, with all parties bearing their own costs. No merits ruling was issued.
Bayer and Meda asserted US8518919B2 (App. No. US13/294069), US9919050B2 (App. No. US13/974881), and US8071073B2 (App. No. US11/284109). All three relate to azelastine hydrochloride nasal spray formulations at 0.2055 mg per spray.
A dismissal without prejudice under FRCP 41(a)(1) carries no preclusive effect. Bayer and Meda retain the legal right to refile infringement claims against Padagis on the same three patents. The patents themselves remain presumptively valid and enforceable, as no invalidity or unenforceability finding was made.
The public record does not disclose the reason for the early dismissal. The 118-day timeline and symmetric ‘own costs’ clause are consistent with a private licensing or consent agreement, a withdrawal of Padagis’s ANDA submission, or another commercial accommodation. These terms, if they exist, are not reflected in the public docket.
The three Bayer/Meda patents — US8518919B2, US9919050B2, and US8071073B2 — remain active and unchallenged on the merits following this dismissal. Companies developing products at this concentration should conduct a current FTO analysis against all three patent families, including any Orange Book-listed continuations, before advancing regulatory filings.
PatSnap Eureka searches patents and litigation data to answer instantly.